Breaking news

Theramir Secures €525,000 To Propel Cancer Therapy To Clinical Phase

by THEFUTURE.TEAM

July 23, 2024

In a significant boost to its pioneering cancer treatment research, Theramir has successfully raised €525,000 in a bridge funding round. This capital injection is poised to support the company’s operations through the latter half of 2025, targeting a critical milestone: the initiation of clinical trials for their innovative therapy, EVmiR.

EVmiR, now patented by the European Patent Office, represents a novel approach in cancer treatment. By utilising extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumours, Theramir aims to target oncoproteins—key regulators of cancer cell growth. This precision method promises fewer side effects compared to traditional treatments such as chemotherapy. The company’s technology has demonstrated efficacy in treating metastatic breast cancer and is now being tested for pancreatic and bladder cancers.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Theramir, co-founded by Marianna Prokopi-Demetriades and Costas Pitsillides in 2016, emerged from a passionate pursuit to find a cure for cancer. Their unique technology capitalises on EVs’ natural ability to transport biological information, essentially turning them into couriers that deliver tumour-suppressive messages via miRNAs. This method requires a detailed genetic profile of the patient to enhance the therapy’s precision and effectiveness, potentially offering prophylactic benefits by identifying genetic markers linked to high-risk conditions.

The latest funding round saw participation from notable investors, including Yannos Palate, a former executive at Eli Lilly, who will join Theramir’s advisory board. His extensive experience in life sciences and pharmaceutical engagement is expected to be instrumental in forging strategic partnerships with major pharmaceutical companies. Other investors include Nicosia-based family office Exerte Partners and finance and corporate lawyer Nancy Erotocritou.

Despite the challenges posed by the limited local life-sciences ecosystem in Cyprus, Theramir has managed to attract significant investor interest, raising €2.5 million in total, including €300,000 in grants. The company’s innovative approach and lower research costs compared to major biotech hubs like Boston or London have contributed to its success.

Looking ahead, Theramir is actively seeking a licensing deal with a major pharmaceutical firm to support the clinical trials, which could span up to seven years. The co-founders are optimistic about expediting the timeline through process efficiencies, projecting a market-ready therapy by 2030. In the interim, they are also exploring new revenue streams, such as using EVmiR to treat chronic malignant wounds through a project named MIRACULOUS, which has secured additional funding.

The Future Forbes Realty Global Properties

Celestyal Cruise Line Revives Mediterranean Operations Amid Strategic Maritime Transit

by THEFUTURE.TEAM

April 27, 2026

Celestyal Cruises has returned its two main vessels, Celestyal Discovery and Celestyal Journey, to the Mediterranean following transit through the Strait of Hormuz and the Suez Canal. The return allows the company to proceed with its summer schedule, with sailings from Athens set to begin on May 1.

Strategic Passage And Operational Coordination

The cruise line reported that both vessels completed their critical transit with distinction, enabled by a well-executed plan that prioritized crew safety and meticulous coordination with international authorities. Celestyal’s operations team, led by industry veteran Captain George Koumpenas, collaborated with regional governments and even received oversight from the US Navy, ensuring a secure journey during uncertain times.

Revitalized Itineraries And Commercial Response

With both ships back in operation, the company is resuming its summer programme. Scheduled sailings include a three-night “Iconic Greek Islands” itinerary starting May 1 on Celestyal Discovery and a seven-night cruise covering Greece, Italy, and Croatia from May 2 on Celestyal Journey. Following a temporary slowdown in bookings, the company is preparing targeted pricing and promotional initiatives to support demand during the peak season, with planning also extending into the autumn period.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Leadership Insights And Future Outlook

Lee Haslett, Chief Commercial Officer at Celestyal, said the return of the vessels has supported booking activity. He noted that weekly business volumes have increased, reflecting improving customer confidence. While short-term demand has been affected, the company expects conditions to stabilize, supported by financial resources and travel partner networks.

Coordinated Maritime Collaboration

Close coordination with other cruise operators defined the return journey, with planning carried out in advance to support a controlled and secure transit. Celestyal Journey participated in a convoy of international vessels, contributing to an organized passage through key maritime corridors. This coordinated approach enabled operators to manage risks collectively and maintain operational continuity during a period of heightened regional uncertainty.

Experienced captains and operational crews played a central role, ensuring alignment across vessels and strict adherence to safety protocols throughout the transit. With both ships now back in service and a revised commercial approach in place, Celestyal Cruises is positioned to continue its summer programme while adapting to current market conditions.